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Abstract  
Here we fabricate and characterise bioactive composite scaffolds for bone tissue engineering 
applications. 45S5 Bioglass® (45S5) or strontium-substituted bioactive glass (SrBG) were 
incorporated into polycaprolactone (PCL) and fabricated into 3D bioactive composite 
scaffolds utilising additive manufacturing technology. We show that composite scaffolds 
(PCL/45S5 and PCL/SrBG) can be reproducibly manufactured with a scaffold morphology 
highly resembling that of PCL scaffolds. Additionally, micro-CT analysis reveals BG particles 
were homogeneously distributed throughout the scaffolds. Mechanical data suggested that 
PCL/45S5 and PCL/SrBG composite scaffolds have higher compressive Young’s modulus 
compared to PCL scaffolds at similar porosity (~75%). After 1 day in accelerated degradation 
conditions using 5M NaOH, PCL/SrBG, PCL/45S5 and PCL lost 48.6 ±3.8%, 12.1 ±1% and 
1.6 ±1% of its original mass, respectively. In vitro studies were conducted using MC3T3 cells 
under normal and osteogenic conditions. All scaffolds were shown to be non-cytotoxic, and 
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supported cell attachment and proliferation. Our results also indicate that the inclusion of 
bioactive glass (BG) promotes precipitation of calcium phosphate on the scaffold surfaces 
which leads to earlier cell differentiation and matrix mineralisation when compared to PCL 
scaffolds. However, as indicated by ALP activity, no significant difference in osteoblast 
differentiation was found between PCL/45S5 and PCL/SrBG scaffolds. These results suggest 
that PCL/45S5 and PCL/SrBG composite scaffold shows potential as a next generation bone 
scaffold. 
 
Keywords: bioactive glass, additive manufacturing, 3D scaffold, polycaprolactone, 
composite scaffolds 
 
 
1. Introduction 
Bone has the unique healing potential for self-repair after an injury. These self-healing capabilities 
can be impeded beyond a certain critical size and thus requires a platform to reunite and regenerate 
the fracture region. Three-dimensional (3D) scaffolds have been used to provide a local environment 
for cells, serving as temporary matrix to support/direct cellular growth/differentiation and to provide 
mechano-induction and ultimately bone remodelling.  Presently, scaffolds employed are polymer-
based which lack bioactivity and are not high load bearing. Their tendency to creep and deform 
permanently under mechanical stresses require reinforcements using metallic plates in order to 
support the defect region during the early stages of bone healing. Hence, the field is moving towards 
the development of composite scaffolds that have mechanically supportive structures that can resist 
creep failure. Other scaffold design considerations include material type and their associated 
degradation properties, biocompatibility, intrinsic microarchitecture, porosity and suitable surface 
chemistry for guiding cellular behaviour and integration with host tissue. To further enhance the 
effectiveness of graft integration with the host defect; one can functionalise the scaffold surfaces with 
appropriate inorganic materials to allow better osseous tissue ingrowth, thus promoting full graft 
integration over long-term implantation which is crucial in preventing loosening and resurgery. 
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Calcium phosphates (CaP), particularly hydroxyapatite (HA), have been used as a biomaterial for 
skeletal implantation for many decades due to their high content present in bone mineral. HA supports 
bone growth directly along its surface when placed in the vicinity of host bone; however this occurs at 
a slow rate. A potential method of improving HA bioactivity is to adjust its chemical composition to 
that of bone mineral, by adding trace amounts of beneficial elements such as silicon, zinc, strontium 
or magnesium which are known to play a significant role in the bone biochemistry. Therefore, more 
recently a range of inorganic bioactive glasses (BG) have been developed and widely used in clinical 
settings to repair hard tissues in a variety of craniofacial, maxillofacial and periodontal applications 
due to their inherent bioactivity [1, 2]. However, BGs are brittle [3], thus limiting their application in 
load bearing/tension applications.  
In this study, PCL was incorporated with one of 2 types of BG, and was used to fabricate composite 
scaffolds by the method of melt extrusion. PCL is an suitable candidate for bone implants due to its 
good rheological and viscoelastic properties compared to other synthetic polymers [4]. Its low melting 
temperature (approximately 60°C) makes PCL easy to be fabricated into 3D constructs [4]. 
Additionally, PCL has been approved by the FDA for tissue engineering applications [5], thus will 
accelerate the transition of the yielded product into a clinical setting. However, PCL is inherently 
hydrophobic and lacks bioactivity [4]. Therefore, to increase the bulk hydrophilicity and bioactivity of 
PCL, BG was incorporated to provide a composite scaffold. As reported by Li et al. [6], incorporation 
of BG into the polymer bulk increases the composite material hydrophilicity and bioactivity [6].  
 
In this study, two different types of BG were used; (1) 45S5 Bioglass® (45S5) containing 46.46 SiO2 –
1.07 P2O5 –26.38 Na2O– 23.08 CaO (mol%) and (2) strontium-substituted bioactive glass (SrBG) 
containing 46.46 SiO2 –1.07 P2O5 –26.38 Na2O– 23.08 (3SrO:1CaO) (mol%) [7]. Both BGs have been 
shown to promote bone formation in vitro and in vivo [8-11]. It has been reported that SrBG has 
enhanced potential in bone regeneration compared to 45S5 bioglass [7] as it is known that strontium is 
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an important trace element in human bone. Sr2+ was also found to induce osteoblast activity by 
stimulating bone formation and reducing bone resorption [12, 13]. 
 
Additive manufacturing techniques enable the  fabrication of biomaterials into 3D scaffolds with 
100% pore interconnectivity, controlled porosity and controlled geometrical structure [14, 15]. This 
technology has provided a promising platform for the development of so-called off the shelf as well as 
patient-specific scaffolds as the next generation of treatment options for bone regeneration as reported 
by various research groups across the world [16-22]. In this study, the proposed bioactive composite 
material will be amalgamated with 3D printing technology for the production of bioactive composite 
scaffolds. The fabricated scaffolds were characterised and subjected to in vitro studies for the 
assessment of bone formation ability.  
 
2. Methods 
 
 
2.1 Preparation of PCL/BG composite material 
45S5 or SrBG (particle size ≤38 µm) were incorporated into the PCL bulk by fast precipitation into 
excess ethanol [23]. Briefly, 10% (w/v) PCL solution was prepared by dissolving 20 g of PCL pellet 
(CAPA 6500, Perstorp, United Kingdom) in 200 ml of chloroform (MERCK Millipore, Australia) at 
room temperature. Then, 10 wt% of BG relative to the PCL mass was added into the PCL solution 
and stirred until a homogenous mixture was achieved. The PCL/BG solution mixture was then 
precipitated into 5-fold excess of 100% ethanol (MERCK Millipore, Australia). The solid PCL/BG 
composite was then isolated and air dried.  
 
2.2 Scaffold fabrication & characterization 
All scaffolds were fabricated using melt extrusion based additive manufacturing technology [24]. 
Briefly, PCL, PCL/45S5 or PCL/SrBG composite was loaded into the material reservoir and the PCL 
was melted by setting the heating inductor coils to 100°C for PCL.  By qualitative observations, the 
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viscosity of PCL/45S5 and PCL/SrBG was higher compared to PCL. Therefore, the temperature was 
raised to 110°C to allow continuous extrusion. As pressure was applied, molten material moved 
towards the rotating screw chamber and extruded through the nozzle tip aided by the rotational 
movement of the screw. All scaffolds were designed and fabricated with a lay-down pattern of 0-90°, 
filament gap of 2 mm and layer thickness of 0.4 mm. Scaffolds of 50 × 50 × 2.4 mm were fabricated 
and cut to 4 × 4 × 2.4 mm for all in vitro studies. All scaffolds were fabricated using a 21G nozzle.  
 
2.3 Surface morphology, porosity, and BG distribution  
The surface morphology of the fabricated scaffolds was examined using scanning electron 
microscopy (SEM) (Quanta 200 SEM- FEI) at 10 kV after gold sputter-coating. Scaffolds porosity 
and the distribution of BG particles within the scaffolds were examined using Micro-CT 40 scanner 
(Scanco Medical, Brüttisellen, Switzerland) at a voxel size of 6 µm. Samples (n = 8) were evaluated at 
a filter width of 1.0 pixels,  filter support of 2.0 pixels and lower threshold of 2% for PCL elements, 
9% for 45S5 and SrBG elements.  
 
2.4 Compressive Young’s modulus 
Mechanical compression tests were conducted using an Instron 5848 microtester fitted with a 500N 
load cell (Instron, Australia).  Scaffolds (n = 6) were subjected to 10% compression at a rate of 1 mm 
min-1 and the compressive Young’s modulus of the scaffolds was determined using the initial linear 
portion of the  stress versus strain data. 
 
2.5 Accelerated in vitro degradation 
Degradation of scaffolds (n = 8) was studied using an accelerated hydrolysis reaction as described by 
Lam et al. [25]. Scaffolds were immersed in 5M sodium hydroxide (Sigma-Aldrich) and maintained 
at 37°C. Scaffolds were removed at daily time-points for up to 7 days. At designated time-points, 
scaffolds were rinsed with dH2O, and dried under vacuum for 48 hours before further evaluation. The 
percentage of mass loss from each individual scaffold was determined using the following equation: 
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 × 100 
The mass of scaffolds was measured using an electronic balance with 0.1 mg resolution.  
 
At respective time-points, scaffold morphology and surface topography were subjected SEM imaging 
as described previously. 
 
2.6 In vitro studies  
All scaffolds were surface treated with 5M NaOH at 37°C for 2 hours to increase the scaffold surface 
hydrophilicity to promote initial cell attachment [26], as well as to increase the exposure of BG 
particles embedded within the PCL bulk at the scaffold surface. Prolonged scaffold surface treatment 
with 5M NaOH was avoided to prevent excessive dislodging of BG particles from the scaffold 
surfaces.  Prior to cell seeding, scaffolds were sterilised by immersion in 70% ethanol for 1 hour and 
UV-sterilisation for 20 minutes on each surface.  
 
2.6.1 Bioactivity. Scaffolds were immersed in α-MEM (Life Technologies) at 37°C for a period of 28 
days. Each scaffold (dimensions 4 × 4 × 2.4 mm) was immersed in 6 ml of α-MEM. At 6 hours, 1, 2, 
3, 7, 14, 21 and 28 days, the concentration of Ca2+, PO43-, Si4+ and Sr2+ in the α-MEM was quantified 
using Vista MPX Inductively Coupled Plasma - Optical Emission Spectrometer (ICP-OES, Varian, 
USA) and pH was measured using a pH meter. 
 
2.6.2 Cell culture. Murine-derived preosteoblast cell line (MC3T3-e1) passage 8 were used for all cell 
culture experiments. Cells were maintained T75 tissue culture flasks with growth media consisting of 
α-MEM media, 10% (v/v) foetal bovine serum (FBS) and 1% (v/v) penicillin/streptomycin. During 
cell seeding, each scaffold was initially seeded with 60 µl of cell suspension (12,000 cells/ scaffold) in 
48-well plates. The pre-seeded scaffolds were incubated at 37°C for 90 minutes before being topped 
up with 700 µl of α-MEM growth media. After 24 hours, half of the cultures were changed to 
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osteogenic induction media, consisting of growth media supplemented with 10 mM glycerol 2-
glycerophosphate, 50 µg/mL L-ascorbic acid-2-phosphate and 100 nM dexamethasone (Sigma). From 
here on, the cell seeded scaffolds will be referred to as cell/scaffold constructs. 
 
2.6.3 Cell morphology. At day 3, 7, 14, 21 and 28, cell/scaffold constructs were retrieved and 
processed accordingly for the assessment of cell morphology using SEM and confocal laser scanning 
microscopy (CLSM).  
SEM: Briefly, cell/scaffold constructs were fixed with 3% (w/v) glutaraldehyde then washed 
thoroughly with 0.1M cacodylate buffer. The samples were treated with 1% (w/v) Dalton osmium 
tetraoxide before being dehydrated sequentially with ethanol solutions. In order to preserve 
cell/scaffold constructs’ surface detail, they were air dried by evaporation of hexamethyldisilazane 
(HMDS) before being sputter coated with gold using Biorad SC500 and imaged using SEM.  
CLSM: The cell attachment onto scaffold surfaces was visualised using actin staining and nuclei 
staining. Briefly, cell/scaffolds constructs were fixed in 4% (w/v) paraformaldehyde (PFA), 
permeabilised with 0.2% (v/v) Triton X-100/PBS, and stained with 0.8 U/ml rhodamine-conjugated 
phalloidin (Invitrogen) and 5 µg/ml 4’,6-diamino-2-phenylindole (DAPI, Invitrogen) in 0.5% (w/v) 
BSA/PBS. Then, cell/scaffold constructs were washed with dH2O to remove excess stain. Viewing 
and analysis were performed using the Leica TCS SP5 Confocal Microscope. 
 
2.6.4 Scaffolds’ cytotoxicity. Scaffold cytotoxicity was determined using MTT (3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay. MTT, a yellow tetrazole, is reduced to 
purple formazan in living cells, thus allowing the assessment of cell viability [27]. In brief, on day 1, 
3, 7 and 14 days; cell/scaffold constructs (n = 6) were transferred to a new 48-well plate. Immediately, 
500 µl of fresh media and 20 µl of MTT solution (5mg/ ml in PBS) (Sigma) were added to each well 
and cell/scaffold constructs were incubated at 37°C for 4 hours, after which the media was aspirated 
and the MTT-formazan product was solubilised with 200 µl of dimethyl sulfoxide (DMSO) (MERCK 
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Millipore) and transferred to a 96-well plate. Absorbance was read at 540 nm with a microplate 
reader.   
 
2.6.5 Cell differentiation. At day 7, 14, 21 and 28, alkaline phosphatase (ALP) enzyme activity, an 
early osteoblasts differentiation marker, was quantified using a colorimetric assay. The cell/scaffold 
constructs (n = 4) were washed with PBS and incubated in 0.2% (v/v) Triton-X in 1x Tris-EDTA (TE) 
solution at -20°C for 10 minutes. Cell lysates were collected and centrifuged at 10,000 rpm for 10 
minutes at 4°C, after which 100µl of the cell lysate supernatant were incubated with 200µl of p-
nitrophenylphosphate (1 mg/ml) in 0.2 M Tris buffer (Sigma-Aldrich) in 96-well plates. After 30 
minutes, the absorbance was measured using a Polar Star Optima plate reader at 405 nm. ALP activity 
was normalised against the sample DNA content, determined using Quant-iT PicoGreen dsDNA assay 
kit (Invitrogen) according to the manufacturer’s protocol. Briefly, the cell lysate retrieved from ALP 
assays were diluted with 1x TE buffer in a 1:1 ratio. Then, 100µl of the diluted cell lysate was pipette 
into opaque 96-well plates followed by 100µl of the Quant-iT PicoGreen aqueous working solution 
and incubated for 5 minutes at room temperature on a rocker plate. Fluorescence was measured with a 
Polar Star Optima plate reader (BMG Labtech, Offenburg, Germany) at an excitation wavelength of 
485 nm and an emission wavelength of 520 nm. 
 
2.6.6 Matrix mineralisation. At day 7, 14, 21 and 28, the extent of matrix mineralisation on the 
cell/scaffold constructs (n = 3) were semi-quantified using Alizarin red staining, which binds to the 
Ca2+ of calcium deposition. Briefly, the cell/scaffold constructs were washed twice with PBS and 
fixed using ice-cold methanol for 10 minutes at room temperature. The cell/scaffold constructs were 
washed with distilled water (dH2O) and incubated with 1% (w/v) Alizarin red S (Sigma-Aldrich) in 
dH2O, pH 4.1, for 10 minutes on a rocker plate. After which, unincorporated dye was washed away 
using several rinses of dH2O and scaffolds were air-dried. For semi-quantification of the staining, 
10% (v/v) acetic acid was added to each well and incubated at room temperature for 30 minutes. The 
cell/scaffolds constructs were mechanically agitated and the resultant lysate was transferred to a 1.5 
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ml microcentrifuge tube and vortexed for 30 seconds. Following this, 300 µl of mineral oil was added 
to each eppendorf tube and samples were heated at 85°C for 10 minutes, then, placed on ice for 10 
minutes. After centrifugation at 20,000 x g for 15 minutes, 500 µl of the supernatant was transferred 
to a new 1.5 ml eppendorf tube and 200 µl of 10% (v/v) ammonium hydroxide was added to 
neutralise the acid. Next, 150 µl of each sample was transferred to 96-well plates in triplicates and 
absorbance was read at 405 nm using a Polar Star Optima plate reader. It should be noted that the 
Alizarin red S dye was shown to stain the composite scaffolds in areas of BG inclusion giving false 
positive readings. Thus, to negate this effect, at all time-points, acellular scaffolds immersed in culture 
medium were used as empty controls to enable the subtractions of background reading.   
 
2.7 Data Analysis 
All data were represented as mean ± SD and were subjected to one-way analyses of variance (one-
way ANOVA) and Tukey’s post-hoc test (SPSS Version 11.02). Significance levels were set at 
p<0.05. 
 
3. Results and Discussions 
 
3.1 Characterisation of scaffolds 
All fabricated scaffolds were shown to have similar scaffold morphologies (figure 1(a-l)). From figure 
1(c, g and k), it was shown that microfilaments of PCL/45S5 and PCL/SrBG scaffolds were rougher 
when compared to PCL scaffolds. From the 3D µCT reconstructed images, both PCL/45S5 (figure 
1(h)) and PCL/SrBG (figure 1(l)) scaffolds showed a homogenous distribution of glass particles 
across the PCL bulk. The axial pores of the scaffolds were larger than the transverse pores of the 
scaffolds. This was confirmed by µCT measurements (figure 2(a)), where the smaller pore sizes 
reflect the transverse pores of the constructed scaffolds as seen in figure 1(b, f, and j). The larger pore 
sizes reflect the axial pores of the scaffolds as seen in figure 1(a, e, and i). From figure 2(a), it is 
noticeable that PCL/45S5 and PCL/SrBG scaffolds generally have higher percentage of lower range 
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pore sizes as compared to PCL scaffolds. This difference was likely because during the scaffold 
fabrication process, a phenomenon known as microfilament sagging (Figure 1(j)) may occur in 
PCL/45S5 and PCL/SrBG scaffolds, thus contributing to the smaller pore sizes. This may have 
resulted from the delayed cooling and solidification of the microfilaments due to the slightly higher 
temperature required for the fabrication of composite scaffolds, hence solidification of the 
microfilament would be slightly longer. Also, after a long period of extrusion time, a small fraction of 
BG particles may accumulate on the extrusion nozzle tip and when it is extruded; this may result in 
heavier microfilaments, contributing to the sagging of microfilaments. The sagging of microfilaments 
occurred randomly during scaffold fabrication and was independent of the axial pore size. 
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Figure 1: SEM and micro-CT imaging of PCL, PCL/45S5, and PCL/SrBG scaffolds. (a – d) PCL 
scaffolds. (e - h) PCL/45S5 scaffolds. (i – l) PCL/SrBG scaffolds. (a, e, i) SEM images of scaffolds 
from top view. (b, f, j) SEM images of scaffolds from transverse view. (c, g, k) SEM images of 
scaffolds showing good fusion of polymer microfilaments between layers (red arrow). (d, h, j) 
Scaffold 3D reconstruction images of micro-CT. 45S5 (h) and SrBG (l) particles (red) are 
homogenously distributed across the PCL bulk. 
 
3.2 Compression modulus of scaffolds 
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The compressive Young’s modulus of PCL scaffolds was found to be 42.19 ±1.51 MPa (figure 2(b)). 
This value is in line with literature which shows that the compressive Young’s modulus for PCL 
scaffolds with porosity between 70-85% lie within the range of 30 MPa to 50 MPa [28, 29]. The 
addition of BG increased the scaffold compressive Young’s modulus, with values of 48.35 ±2.57 MPa 
for PCL/45S5 scaffolds and 59.18 ±0.97 MPa for PCL/SrBG scaffolds (figure 2(b)). The increase in 
composite scaffolds’ compressive Young’s modulus was expected as it has been previously reported 
by Shor et al. [29] that inclusion of hydroxyapatite particles (25 wt%, 10-25 µm) into the PCL bulk 
increases the scaffold compressive Young’s modulus regardless of the scaffold porosity. Korpela et 
al. [30] and Jiang et al. [31] also illustrated that inclusion of 10 wt% BG particles (<50 µm) and 10 to 
40 wt% of hydroxyapatite particles (2.1 ±0.4 µm) respectively, into PCL scaffolds increases the 
scaffolds’ compressive Young’s modulus. Collectively, PCL/BG scaffolds have better stiffness than 
PCL scaffolds which might be well suited for hard tissue engineering. The compressive Young’s 
modulus of PCL/SrBG scaffolds was found to be significantly higher compared to PCL/45S5 
scaffolds.  The cause behind this phenomenon is unclear however we speculate that this might 
attributable to the difference in the silicate-glass network of 45S5 and SrBG. It is reported that 
substitution of calcium for strontium leads to expansion of the SrBG silicate-glass network [32-34] 
and suppresses the crystallisation of orthophosphate phase in SrBG which  is present in 45S5 [32]. In 
line with this, it is reported that crystalline structure and size within a composite system can affect the 
interfacial adhesion between the matrix (PCL in our case) and the filler (45S5 or SrBG in our case); 
which in turn affects the mechanical performance of the composite (PCL/45S5 or PCL/SrBG) [35, 
36]. This finding is in agreement with the conclusion reached by Gerhardt et al. [37] who described 
that the composition of the glass phase affects the mechanical properties of scaffolds although the 
actual mechanism of interfacial interaction between 45S5 and SrBG with PCL is not clear.   
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Figure 2: (a) Porosity and pore size distribution of PCL, PCL/45S5 and PCL/SrBG scaffolds.  (b) 
Axial compressive modulus of PCL, PCL/45S5 and PCL/SrBG scaffolds (n =6). Mean ± S.D. * 
indicate significantly higher (p < 0.05) compressive modulus compared to PCL scaffolds. † indicates 
significantly higher (p < 0.05) compressive modulus compared to PCL/45S5 scaffolds. 
 
3.3 Accelerated in vitro degradation of scaffolds 
The main mode of initial degradation of high-molecular weight polyesters is via random hydrolytic 
scission [32]. The cellular degradation (also known as biodegradation) only takes place during the 
later stage, involving only low molecular weight (Mn < 5000) polyester that could feasibly be 
recognized and ingested by phagocytes [32]. Thus, to recapitulate the initial degradation of PCL in 
vitro, we opted to utilise 5M NaOH to enhance the hydrolysis of PCL; this would also mimic the 
physiological condition but at an accelerated rate [33].   
 
The accelerated degradation studies were conducted for up to 7 days in 5M NaOH, after which time 
neither PCL/45S5 nor PCL/SrBG could be retrieved for further analysis owing to complete 
breakdown. Over 7 days of immersion in 5M NaOH, PCL scaffolds only lost 24.7 ± 1.6% of their 
original mass (figure 3(d)). PCL scaffold surfaces were roughened due to the hydrolytic degradation 
of PCL on the surface, but the overall structure of scaffolds remained intact (figure 3(a)). PCL/45S5 
scaffolds lost their mass steadily over time when immersed in 5M NaOH (figure 3(d)), and the 
scaffold microfilaments reduced in size over time (figure 3(b)). It was also observed that as the PCL 
degraded, the 45S5 particles dislodged from the PCL microfilament, leaving numerous pits on the 
scaffold surfaces (figure 3(b)). After 7 days of immersion in 5M NaOH, PCL/45S5 scaffolds were not 
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retrievable for further analysis (figure 3(b)) as all scaffolds had disintegrated into pieces. The 
degradation rate of PCL/SrBG was faster compared to PCL and PCL/45S5 scaffolds.  After 1 day of 
immersion in 5M NaOH, PCL/SrBG scaffolds lost 48.6 ±3.8% of their original mass, compared to 
12.1 ±2% and 1.6 ±1% for PCL/45S5 and PCL scaffolds, respectively (figure 3(d)). After 2 days of 
immersion, PCL/SrBG scaffolds were no longer retrievable for further analysis (figure 3(c)). Similar 
studies undertaken by Lam et al.[25] into the degradation of PCL scaffolds incorporated with 20 wt% 
tri-calcium phosphate particles (<60 µm) (PCL/TCP) show similar outcomes; PCL/TCP scaffolds 
were completely degraded after 54 hours of immersion in 5M NaOH compared to 6 weeks for PCL 
scaffolds [25]. Taken collectively, the rates of degradation of these scaffolds were: PCL/SrBG > 
PCL/TCP > PCL/45S5 > PCL scaffolds. Factors including particles size, wt% of particles inclusion, 
and composition of particles contributed to these degradation differences. Further comparison studies 
are needed to determine the key factors. 
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Figure 3: Pictures and SEM images of (a) PCL, (b) PCL/45S5 and (c) PCL/SrBG scaffolds for 1, 3, 
5, and 7 days in 5M NaOH. For PCL/45S5 (day 7) and PCL/SrBG (day 2 onwards), as shown in the 
below picture, scaffolds were disintegrated into pieces and not retrievable for further analysis. * Pits 
on PCL microfilaments due to dislodged of BG particles. (d) Graph showing the percentage of mass 
loss of PCL, PCL/45S5 and PCL/SrBG scaffolds over time. Mean ± SD. 
 
Overall, we demonstrated the accelerated degradation of PCL/45S5 and PCL/SrBG composite 
scaffolds compared to PCL scaffolds. Melt extruded PCL scaffolds have relatively smooth surfaces 
(figure 1(c)). The inclusion of BGs into PCL bulk for melt extrusion yielded composite scaffolds 
(PCL/45S5 and PCL/SrBG) with micro-pores on the scaffold microfilament surfaces (figure 1(g, k)). 
These micro-pores served to increase the surface area for hydrolytic degradation and thus increased 
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the degradation rate of the composite scaffolds. Additionally, BG particles are highly hydrophilic [2], 
which increases media diffusion into the microfilament bulk and increases residual media in the 
micro-voids at the PCL and BG particles interface [25]. The coupling of these micro-voids and 
dislodging of BG particles increases the interfacial surface area for media intrusion and attack, which 
in turn increases the scaffolds degradation for the composites; PCL/45S5 and PCL/SrBG compared to 
scaffolds comprising PCL alone. 
 
We also demonstrated that the degradation rate of PCL/SrBG scaffolds was faster than PCL/45S5 
scaffolds. As previously described, the SrBG used in this study were formulated by the substitution of 
the calcium for strontium within the silicate glass network. Calcium is known as a network modifier 
in the silicate glass system. O’Donnell et al. [34] and Wu et al. [35] have reported that the substitution 
of calcium for strontium can lead to the expansion of the silicate glass network due to the lower 
charge to size ratio of Sr2+ (ionic radius = 1.12 Å),  compared to Ca2+ (ionic radius = 0.99 Å)  [7, 34, 
35]. The expansion of the silicate glass network leads to the weakening of the glass network, resulting 
in higher dissolution rates of the SrBG. In the context of composite scaffolds comprising a polymer 
matrix combined with bioactive glass particles, the higher dissolution rate of SrBG particles leads to 
increased interfacial surface area for media intrusion and attack within a short period of time; thus, 
resulting in faster degradation rates for PCL/SrBG scaffolds compared to PCL/45S5 scaffolds. 
 
3.4 Bioactivity of scaffolds 
The study of in vitro scaffold bioactivity using culture media or stimulating body fluid (SBF) has 
always been much debated [36-39]. We have studied the in vitro bioactivity using culture media (α-
MEM) as commercially available α-MEM is a more controlled source compared to laboratory 
prepared SBF. Additionally, all our cell culture studies were performed using α-MEM media, thus, the 
bioactivity studies outcomes will be more reflective of our cell culture studies outcomes. 
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We assessed the changes of ionic concentration of Ca2+, PO43-, Si4+ and Sr2+, in the culture media 
immersed with either PCL, PCL/45S5 or PCL/SrBG scaffolds, as shown in figure 4 (a-d). The Ca2+ 
concentration (figure 4(a)) across all groups remained fairly constant up to 3 days of incubation.  As 
incubation time was lengthened, the Ca2+concentration in the culture media of PCL group decreased 
from day 3 to day 7, followed by a fairly constant level for up to 28 days of incubation. In contrast, 
the Ca2+ concentration in the media of PCL/45S5 and PCL/SrBG groups gradually decreased until the 
end of experiments. Despite the release of Ca2+ from 45S5 and SrBG, the depletion of Ca2+ from 
culture media is most likely due to the formation of a calcium phophate layer on the scaffolds surfaces 
during incubation as shown in figure 4(e). This finding coincides with the decrease of PO43- 
concentration (figure 4(b)) from day 3 to 28 and the percipitation observed on PCL/SrBG scaffolds 
surfaces at day 28 via SEM (figure 4(e)). At the end of experiments (28 days), no precipitation was 
observed on PCL scaffold surfaces via SEM (data not published), which reflects the ICP data 
presented. 
 
Si4+ and Sr2+ have been shown to play a role in stimulating cells during bone formation [40]. From day 
0 to 3, both dissolution media of PCL/45S5 groups and the PCL/SrBG groups indicated an initial 
rapid increase of Si4+ concentration. From day 3 to day 21, the  Si4+  level of PCL/SrBG groups 
remained relatively constant and further increased from day 21 to 28. The  Si4+  level of PCL/45S5 
groups remained relatively constant from day 3 thorugh to day 28 (figure 4(c)). The increase in Si4+ 
concentration  was contributed to by the breakup of the outer silica layers (Si-O-Si bond) of the BG 
network [3]. We hypothesise that the steady level of Si4+  detected in the media during incubation was 
due to the depletion of the BG exposed on the PCL microfilament surfaces. Over time, as PCL was 
degraded and media was able to diffused through the PCL microfilaments via the pits on 
microfilament surfaces (surfaces previously occupied by BG which has dissolved/dislodged to the 
surrounding media), more BG may come into contact with the immersion media, thus  increasing the 
level of Si4+. The concentration of Sr2+ for PCL/SrBG increased over the incubation time following 
the similar trend of Si2+ dissolution ion profile. Taken together, the data suggests that BG incorporated 
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into PCL bulk can act as a long term reservoir of BG and will enable a constant diffusion of ions 
which are implicated in bone formation into the local microenvironment.  
 
The pH of the culture media immersed with PCL remained fairly constant throughout the 28 days as 
shown in figure 4(f). After 24 hours immersion of either PCL/45S5 or PCL/SrBG, the pH of culture 
media increased from the basal level (pH 7.21±0.01) to pH 7.35±0.01 and pH 7.32±0.01, respectively. 
Thereafter, the pH remained fairly constant as shown in figure 4(f). The increase in pH observed in 
PCL/45S5 and PCL/SrBG immersion media is likely caused by the dissolution of glass modifier (Na+ 
and K+). A similar phenomenon but higher pH value has been observed by Fu et al. [22] and Russias 
et al. [20] when immersing 6P53B glass scaffold or 6P53B glass (70wt%)/polylactide scaffolds into 
SBF. The higher pH value observed by Russias et al. [20] may contribute to the  denser apatite crystal 
layer formed on the surface of 6P53B glass/polylactide scaffolds compared to the thin layer of apatite 
crystal colonies observed on  the PCL./SrBG scaffold (figure 4(e)). Higher pH values indicate a 
higher level of free BG dissolution ions (Na+, K+, Sr2+ etc.). This increases the rate of ion exchange of 
Na+ from the glass with H+ and H3O+ from surrounding solution, followed by a polycondensation 
reaction of surface silanols to create high-surface area for heterogeneous nucleation and crystallisation 
of a biologically reactive hydroxy-carbonate apatite (HCA) layer [1]. 
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Figure 4: (a-d) Ca2+, PO43-, Si4+ and Sr2+ concentration from scaffolds dissolution test. Mean ± S.D. (e) 
SEM images of PCL/SrBG scaffolds after 28 days of immersion in culture media. (f) pH value of 
media immersed with PCL, PCL/45S5 or PCL/SrBG. Mean ± S.D. 
 
3.5 Cell morphology  
As shown in the SEM and confocal images in figure 5(a, g, and m) and (d, j and p) respectively, after 
3 days of culture, cells were well attached onto all scaffold microfilaments. By day 14 (figure 5(d, e, 
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h, k, n, and q)), a dense and continuous layer of cell sheet (cell and cell matrices) were formed along 
the scaffold’s microfilaments. On day 28 (figure 5(c, f, i, l, o, and r)), it was observed that cell sheet 
had begun to bridged across scaffold’s microfilaments. This shows that all scaffold groups (regardless 
of material) can support initial cell attachment, cell proliferation and secretion of extracellular 
matrices, leading to the commencement of cell bridging and cell sheet formation across scaffold’s 
microfilament.  
 
Figure 5: SEM (a-c, g-i, and m-o)  and confocal (d-f, j-l, and p-r)  images of PCL (a-f), PCL/45S5 (g-
l) and PCL/SrBG (m-r) cell scaffold constructs cultures for 3 (a, d, g, j, m, and p), 14 (b, e, h, k, n, and 
q) and 28 (c, f, I, l, o, and r) days under osteo-induced condition.  * indicates cell sheet bridging 
across microfilaments. (d-f, j-l, and p-r)   
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3.6 Cytotoxicity 
After scaffolds had been cultured for 7 and 14 days, MTT activity (figure 6) was seen to be increased 
significantly; indicating that all scaffolds (PCL, PCL/45S5, and PCL/SrBG) were non-cytotoxic and 
are able to support cell attachment, growth and proliferation. Furthermore, it was noted on day 3, 7 
and 14, that the MTT activity (figure 6) of PCL/45S5 and PCL/SrBG cultured under control or 
osteogenic-induced conditions had significantly higher MTT activity compared to PCL, suggesting 
that dissolved ions released from the BG (45S5 or SrBG) further enhanced the metabolic activity, and 
hence the proliferation rate of MC3T3 cells.  
 
However, no significant difference was detected between PCL/45S5 and PCL/SrBG constructs. This 
was not in agreement with studies by Gentleman et al. [7] who demonstrated significantly enhanced 
MTT activity of SrBG groups compared to 45S5 group. However it must be noted that these studies 
used pure BG discs with greater availability of BG to elute into the media and exert and effect on the 
cells. This leads to the conclusion that in the present study the amount of SrBG incorporated into the 
PCL bulk was too low, or the exposed particles, at any one time were too few to allow Sr2+ ions to 
exert as strong an effect on the cells as when using SrBG in isolation. However there was clearly a 
significant positive effect of both BG groups compared to PCL-alone in terms of cell metabolic 
activity. 
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Figure 6: Graph showing MTT absorbance at 540 nm of PCL, PCL/45S5 and PCL/SrBG scaffolds 
far day 1, 3, 7, and 14. Mean ± SD; significance at p<0.05. † indicated significantly higher MTT 
activity compare to PCL scaffolds of the respective culture conditions. * indicate significantly higher 
(p < 0.05) MTT activity compared to day 3 of the respective materials and culture conditions. 
 
3.7 Cell differentiation  
ALP activity was assessed to determine the osteogenic potential of composite scaffolds (PCL/45S5 
and PCL/SrBG). To further assessed the osteoinductivity of the composite scaffolds in vitro, the 
constructs were cultured in osteogenic supplemented (osteo) or non-osteogenic supplemented 
(control) media. For constructs cultured under control media, the ALP activity (figure 7) was minimal, 
indicating that no cells differentiated into osteoblasts.  For cell scaffold constructs cultured in osteo 
media, ALP activity (figure 7) was significantly higher compared to their respective control group at 
all time-points, except PCL in 7 days culture. ALP activity was significantly increased on day 28 
compared to all other time points, indicating differentiation of pre-osteoblasts into mature osteoblasts. 
For inter-group comparison, it is worth noting that PCL/45S5 (Day 7, 14, 21 and 28) and PCL/SrBG 
(day 7 and 21) cultured under osteo condition has significantly higher ALP activity compared to PCL 
scaffolds cultured under the same condition. This finding indicates that the dissolution ions of BG has 
a significant contributory effect in promoting the differentiation of osteoblasts, although this effect 
was only evident in the presence of osteogenic media. This phenomena was likely owing to the 
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concentration of ions being insufficient to promote osteogensis alone, this may be overcome in future 
by increasing the BG component (wt%) in the scaffolds. 
 
Figure 7: Graph showing ALP activity of PCL, PCL/45S5 and PCL/SrBG scaffolds at day 7, 14, 21, 
and 28. Mean ± SD; significance p < 0.05. * indicated significantly higher ALP activity compare to 
cell-scaffold construct of the same material cultures under control (non-osteogenic) condition of 
respective days. ‡ indicate significantly higher ALP activity compare to PCL cell-scaffold constructs 
cultured under osteogenic-induced conditions of respective days. † indicated significantly higher ALP 
activity compare to day 21 of the respective materials and culture conditions. 
3.8 Matrix mineralisation 
 
At Day 7 and 14, PCL/SrBG (control and osteo group) show a significantly higher degree of 
mineralisation compared to all other groups (figure 8); indicating that PCL/SrBG can stimulate earlier 
matrix mineralisation. This finding can be attributed to the accelerated dissolution rate of SrBG, and 
consequently the faster degradation rate of PCL/SrBG scaffolds which in turn exposed more SrBG 
particles to the surronding media for dissolution, leading to earlier matrix mineralisation.  
 
With prolonged culture (21 and 28 days), the degree of mineralisation was no different between all 
groups cultured in control media (figure 8). No difference was found in PCL groups cultured under 
control or osteo conditions. However, it was noted that under osteo conditions, PCL/45S5 and 
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PCL/SrBG showed significantly higher mineralisation compared to PCL cultured under the same 
condition, indicating a synergistic effect between the BG dissolution ions and the osteogenic 
supplements in the culture media to promote matrix mineralisation, which was also reflected in the 
ALP readings. This synergistic effect will be an interesting study in the future.     
 
Figure 8: (a) Qualitative visualisation of alizarin red staining on scaffold. (b) Semi-quantitative of 
alizarin red staining intensity on scaffolds. Mean ± SD; significance p < 0.05. * indicated significantly 
higher Alizarin red S stain intensity compare to PCL cell-scaffold construct of the respective culture 
conditions and days. 
 
Our results indicate that the inclusion of BG does promote cell differentiation and matrix 
mineralisation when cultured in osteogenic-induced condition. However, an ultimate aim of a 
biomaterial suitable for bone regeneration is that it is able to induce bone formation in the absence of 
osteogenic-inductive factors (such as growth supplements or growth factors such as BMPs). In order 
to achieve such a goal, the results of this study confirm that the wt% of BG included into the PCL 
bulk has to be significantly increased. In these studies, 45S5 and SrBG of < 38um particles size were 
used. This particle size range sometimes caused blockage of extrusion nozzle during fabrication if 
greater than 10wt% of BG was incorporated into the PCL bulk. To increase the wt% of bioglass 
within the PCL bulk, smaller particles should be considered. In more recent work, BG with particles 
size <20um were obtained and we are thus now able to incorporate 50wt% of BG into the PCL bulk 
and printed it without any difficulty using a 21G nozzle (data not published).   
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4. Conclusion 
Fabrication of PCL scaffolds incorporated with BG is feasible. Our results indicate that inclusion of 
BG can promote MC3T3 cell proliferation, differentiation and matrix mineralisation at early time-
points. However, the initial stimulatory level effect of BG levelled off with prolonged culture. This 
occurrence might be due to lack of BG presence within the scaffold surface. We anticipate that 
inclusion of higher wt% of BG into the PCL bulk and the subsequent fabrication of these composite 
scaffolds will lead to better outcomes. The production of such an off-the shelf bioresorbable and 
bioactive scaffold, as a next generation treatment for bone regeneration would minimise/eradicate the 
need for the addition of growth factors. Furthermore, the ability to rapid prototype anatomically 
precise composite scaffolds enables a patient to be offered a custom-made implant which is an 
appealing goal for any patient and surgeon. 
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